Latest news and press releases about Inhibrx Biosciences Inc. (INBX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function.
Price
| Price | $101.77 |
| Market Cap | $1.5B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -30.10 |
| EV / EBITDA | -12.68 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 1893.60% |
| Return on Invested Capital | -99.35% |
| Return on Assets | -89.60% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AMLX · ATAI · CVAC · ELVN · IMTX · NKTR · ORIC
Explore sector: Healthcare · Biotechnology
More sections of INBX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks